7,031 Shares in Pfizer Inc. (NYSE:PFE) Bought by Great Diamond Partners LLC

by · The Cerbat Gem

Great Diamond Partners LLC acquired a new stake in Pfizer Inc. (NYSE:PFE – Free Report) in the third quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund acquired 7,031 shares of the biopharmaceutical company’s stock, valued at approximately $203,000.

Other large investors have also modified their holdings of the company. Cornerstone Wealth Management LLC grew its holdings in Pfizer by 19.4% in the first quarter. Cornerstone Wealth Management LLC now owns 63,545 shares of the biopharmaceutical company’s stock valued at $1,763,000 after purchasing an additional 10,314 shares during the period. First Trust Direct Indexing L.P. lifted its position in shares of Pfizer by 45.0% during the 1st quarter. First Trust Direct Indexing L.P. now owns 51,735 shares of the biopharmaceutical company’s stock valued at $1,436,000 after buying an additional 16,060 shares in the last quarter. Accel Wealth Management acquired a new stake in Pfizer in the 1st quarter valued at $205,000. American National Bank & Trust Co. VA purchased a new stake in Pfizer in the 1st quarter worth $285,000. Finally, China Universal Asset Management Co. Ltd. acquired a new position in Pfizer during the first quarter worth $315,000. Institutional investors and hedge funds own 68.36% of the company’s stock.

Analyst Upgrades and Downgrades

Several brokerages have recently issued reports on PFE. Daiwa Capital Markets upgraded shares of Pfizer from a “neutral” rating to an “outperform” rating and lifted their target price for the company from $28.00 to $34.00 in a research report on Wednesday, August 7th. Barclays lifted their price objective on Pfizer from $30.00 to $32.00 and gave the stock an “equal weight” rating in a report on Wednesday, July 31st. StockNews.com raised Pfizer from a “hold” rating to a “buy” rating in a report on Wednesday, October 9th. Citigroup initiated coverage on Pfizer in a research note on Friday, October 25th. They issued a “neutral” rating and a $30.00 price target on the stock. Finally, Cantor Fitzgerald reissued an “overweight” rating and issued a $45.00 price objective on shares of Pfizer in a research note on Wednesday, October 23rd. Eight investment analysts have rated the stock with a hold rating, six have issued a buy rating and one has given a strong buy rating to the stock. Based on data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $33.58.

View Our Latest Stock Analysis on PFE

Pfizer Trading Up 0.2 %

Shares of PFE opened at $28.52 on Thursday. Pfizer Inc. has a 12-month low of $25.20 and a 12-month high of $31.54. The firm has a market capitalization of $161.61 billion, a P/E ratio of 38.54, a P/E/G ratio of 0.99 and a beta of 0.67. The firm has a 50-day moving average price of $29.06 and a 200 day moving average price of $28.56. The company has a current ratio of 0.86, a quick ratio of 0.60 and a debt-to-equity ratio of 0.65.

Pfizer (NYSE:PFE – Get Free Report) last posted its quarterly earnings results on Tuesday, October 29th. The biopharmaceutical company reported $1.06 earnings per share for the quarter, beating the consensus estimate of $0.64 by $0.42. The business had revenue of $17.70 billion during the quarter, compared to analysts’ expectations of $14.92 billion. Pfizer had a negative net margin of 4.66% and a positive return on equity of 8.42%. The business’s revenue for the quarter was up 31.2% on a year-over-year basis. During the same quarter in the prior year, the company posted ($0.17) EPS. Sell-side analysts forecast that Pfizer Inc. will post 2.67 EPS for the current year.

Pfizer Announces Dividend

The firm also recently announced a quarterly dividend, which will be paid on Monday, December 2nd. Shareholders of record on Friday, November 8th will be given a $0.42 dividend. The ex-dividend date of this dividend is Friday, November 8th. This represents a $1.68 dividend on an annualized basis and a yield of 5.89%. Pfizer’s dividend payout ratio is currently 227.03%.

About Pfizer

(Free Report)

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.

See Also

Want to see what other hedge funds are holding PFE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Pfizer Inc. (NYSE:PFE – Free Report).